Tracleer Related Published Studies
Well-designed clinical trials related to Tracleer (Bosentan)
Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. [2008.06.23]
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. [2008.06.21]
A randomized, controlled trial of bosentan in severe COPD. [2008.04.30]
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. [2008.01.01]
A Randomized Placebo-Controlled Trial of Bosentan in Patients with Idiopathic Pulmonary Fibrosis. [2007.09.27]
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. [2007.06]
Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. [2007.03]
Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. [2007.01]
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. [2006.12.01]
An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. [2006.11]
Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. [2006.07.04]
Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. [2006.03]
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. [2005.10]
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. [2005.10]
The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. [2005.04]
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. [2005.02]
Survival with first-line bosentan in patients with primary pulmonary hypertension. [2005.02]
Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects. [2005.01]
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. [2004.12]
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. [2004.09]
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. [2003.04.16]
Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. [2003]
Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? [2002.10]
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. [2002.06]
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. [2002.04]
Bosentan therapy for pulmonary arterial hypertension. [2002.03.21]
Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. [2002.03]
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. [2001.10.06]
Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. [2000.07.25]
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. [2000.01]
Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. [1999.08]
Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. [1999.07]
The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. [1999.06]
Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist. [1999.05]
Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. [1998.11.24]
The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. [1998.03.19]
Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. [1997.01]
Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. [1996.10]
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. [1996.08]
Well-designed clinical trials possibly related to Tracleer (Bosentan)
Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger's Syndrome. [2008]
Treprostinil for pulmonary hypertension. [2008]
Evidence-based pharmacologic management of pulmonary arterial hypertension. [2007.10]
Does endothelin play a role in chemoreception during acute hypoxia in normal men? [2007.05]
Sitaxsentan for treatment of pulmonary hypertension. [2007.01]
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. [2006.12]
Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. [2006.09.26]
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. [2006.05.16]
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. [2005.06.01]
[Emerging Therapies for the Treatment of Pulmonary Arterial Hypertension.] [2005.06]
Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. [2004.06]
Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. [2000.04.15]
Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. [1999.06]
Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. [1998.11.24]
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. [1995.09.16]
Other research related to Tracleer (Bosentan)
Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. [2008.09]
A randomised, controlled trial of bosentan in severe COPD. [2008.09]
Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. [2008.08]
Successful treatment with bosentan for refractory digital ulcers in a patient with systemic lupus erythematosus. [2008.07]
Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. [2008.07]
Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. [2008.07]
Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. [2008.06.01]
Bosentan in systemic sclerosis. [2008.06]
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. [2008.05]
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. [2008.05]
N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. [2008.05]
Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. [2008.04]
Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. [2008.03]
Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects. [2008.02.27]
A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. [2008.02]
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. [2008.01]
Role of iloprost and bosentan in pulmonary arterial hypertension. [2008.01]
Current status of bosentan for treatment of pulmonary hypertension. [2008.01]
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study. [2008]
Experience with inhaled iloprost and bosentan in portopulmonary hypertension. [2007.12]
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. [2007.11.27]
Effect of bosentan on the production of proinflammatory cytokines in a rat model of emphysema. [2007.10.31]
Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). [2007.10.20]
Bosentan dans la sclerodermie: Perspectives. [2007.10]
Bosentan et fibrose pulmonaire. [2007.10]
Bosentan et ulceres digitaux. [2007.10]
Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? [2007.10]
Clinical and Hemodynamic Effects of Bosentan Dose Optimization in Symptomatic Heart Failure Patients with Severe Systolic Dysfunction, Associated with Secondary Pulmonary Hypertension - A Multi-Center Randomized Study. [2007.09.17]
Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment. [2007.09]
Results of European post-marketing surveillance of bosentan in pulmonary hypertension. [2007.08]
Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. [2007.08]
Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. [2007.07]
[Observational study of the efficacy and tolerability of bosentan for the treatment of pulmonary hypertension in a tertiary referral hospital] [2007.07]
Treatment of patients with Eisenmenger's syndrome with Bosentan. [2007.06]
Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. [2007.05]
Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. [2007.04]
[Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome] [2007.04]
Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. [2007.04]
[Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)] [2007.04]
Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. [2007.03]
Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. [2007.03]
Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients. [2007.02]
Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. [2007.02]
Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion? [2007.02]
[Role of bosentan in patients with chronic venous thromboembolic pulmonary hypertension] [2007.01.13]
Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. [2007]
Review of bosentan in the management of pulmonary arterial hypertension. [2007]
|
